Longitudinal neuropsychological safety assessment of biperiden treatment following traumatic brain injury.
Maira L Foresti, Eva D Cristino, Viviam Sanabria et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial assessed the neuropsychological safety of biperiden in 54 patients with moderate-to-severe traumatic brain injury (TBI). Cognitive outcomes were evaluated over 20-36 months, revealing no significant differences between biperiden and placebo groups. The study found that TBI severity, lesion distribution, and cognitive reserve were more influential on cognitive performance than the treatment itself.
Key findings
- No differences in cognitive outcomes between biperiden and placebo groups were observed.
- Greater TBI severity correlated with poorer processing speed, working memory, and verbal performance.
- Higher educational level was linked to better performance in specific cognitive domains.
- Biperiden showed no evidence of long-term neuropsychological harm following TBI.
Why it matters
Understanding the neuropsychological safety of treatments like biperiden is crucial for clinicians managing TBI patients. This study suggests that biperiden does not adversely affect cognitive recovery, allowing for its consideration in acute interventions aimed at enhancing neuroplasticity.